Gomekli
Gomekli ingredients
| Active ingredient | Strength |
|---|---|
| Mirdametinib | 2 mg/1, 1 mg/1 |
What Gomekli is used for
The FDA lists the approved uses on the official label (below). In the EU, mirdametinib is approved as Ezmekly for:
Ezmekly as monotherapy is indicated for the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in paediatric and adult patients with neurofibromatosis type 1 (NF1) aged 2 years and above.
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Gomekli
- Generic name
- Mirdametinib
- Made by
- SpringWorks Therapeutics, Inc.
- Forms
- Capsule, Tablet, For Suspension
- Given
- Oral
- Drug class
- Kinase Inhibitor
- FDA approval
- New drug application (NDA) NDA219389
- On the US market since
- 2025
Official information
- MedlinePlus drug information (search for Mirdametinib)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Gomekli?
Gomekli (Mirdametinib) is a cancer medicine made by SpringWorks Therapeutics, Inc., approved by the US FDA.
What are the ingredients of Gomekli?
Gomekli contains Mirdametinib (2 mg/1, 1 mg/1).
Is Gomekli approved in Europe?
The same active substance is approved in the EU as Ezmekly.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA